August 16, 2022 – GSK completes acquisition of Affinivax, Inc. READ MORE >
simple. powerful.
vaccines.
Novel Vaccines Designed to Enhance the Depth and Breadth of Protection against Challenging Infectious Diseases
Affinivax is a clinical stage biopharmaceutical company with a next generation vaccine technology platform called the Multiple Antigen Presentation System (MAPS™). MAPS uses a patented approach to achieve high-affinity binding of two key immunogenic components – polysaccharide and protein antigens – so that both components are able to drive a broad and protective B-cell and T-cell immune response in a single vaccine. We believe the result is a significant step forward in vaccine technology, creating novel preventive and therapeutic vaccines targeting resistant infectious and other immune-mediated diseases.
